Stocksigma LogoStocksigma Logo

Dr. Reddy’s Secures DCGI Approval for Zytorvi in Advanced Esophageal Cancer

Dr. Reddy’s Laboratories received DCGI approval for Zytorvi (toripalimab), in combination with cisplatin and paclitaxel, as a first-line treatment for

Dr. Reddy’s Secures DCGI Approval for Zytorvi in Advanced Esophageal Cancer

Dr Reddys Laboratories Ltd · Press Release · 21 Oct 2026, 3:09 pm

Dr. Reddy’s Secures DCGI Approval for Zytorvi in Advanced Esophageal Cancer Dr. Reddy’s Laboratories received DCGI approval for Zytorvi (toripalimab), in combination with cisplatin and paclitaxel, as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 biomarker status. This marks Zytorvi's second approved indication in India, following nasopharyngeal carcinoma. Phase 3 JUPITER-06 trial data showed the regimen reduced disease or death risk by 42%, extending median overall survival to 17.7 months versus 12.9 months for chemotherapy alone. Dr. Reddy’s holds exclusive licensing rights for toripalimab across 21 countries.

Original exchange filing (PDF)

More announcements from Dr Reddys Laboratories Ltd

All Dr Reddys Laboratories Ltd announcements